The Clinical Implications of RSK1-3 in Human Breast Cancer

HUISHAN ZHAO; TRACEY A. MARTIN; ELERI L. DAVIES; FIONA RUGE; HEFEN YU; YUXIANG ZHANG; XU TENG; WEN G. JIANG

Figure 1.
Expression of RSK1-3 in breast cancer tissues. A: Immunohistochemical staining of RSK1-3 in normal breast tissue (left panel) and tumour tissue (right panel). B: RSK-2 transcripts level was increased in human breast cancer. C: The expression of RSK-3 is higher in normal adjacent tissues.
Figure 2.
Correlation of RSK1-3 expression with Nottingham Prognostic Index (NPI), grade, TNM staging and prognosis. Top panel (RSK-1) A: Levels of expression of RSK-1 in breast tumour tissues in connection with grade and B with TNM status (*p<0.05 vs. TNM1 tumour). C: The predicted prognosis was dependent on the NPI value of patient and that good, moderate and poor prognosis had NPI value either <3.4, 3.4–5.4 or >5.4. (*p=0.046 vs. moderate prognostic group). D: Levels of RSK-1 transcript and clinical outcomes. RSK-1 expression progressively decreased in the patients with local recurrence who died of breast cancer, compared to disease-free patients. E: Higher level of RSK-1 expression in primary breast tumours had a positive correlation with longer disease free survival. (*p<0.05; 0.6 represent low level of RSK-1, 1.00 represent high level of RSK-1). Middle panel (RSK-2) F: RSK-2 expression level in breast cancer tissues was highest in grade 3. Bottom panel (RSK-3) G: Levels of expression of RSK-3 in breast tumour tissues in connection with grade status and with TNM status (*p<0.05, vs. ** p<0.01 TNM1 tumour).
Figure 3.
Effects of RSK inhibitors on the adhesion of breast cancer cells. Top panel: The response of MCF-7 to SL0101-1. A: Traces of MCF-7 cell's response to SL0101-1 at different concentration. B: 3D image of MCF-7 (control); C and D: Response of MCF-7 to SL0101-1 at 9 nM and 90 nM, respectively. Middle panel: The response of MDA MB-231 to SL0101-1. E: Traces of MDA MB-231 cell's response to SL0101-1 at different concentration. F: 3D image of MDA MB-231 (control); G and H: Response of MCF-7 to SL0101-1 at 9 nM and 90 nM, respectively. Bottom panel: The response of MCF-7 (I) and MDA MB-231 (J) to BRD7389 at the concentrations indicated.
Figure 4.
The effect of RSK1-3 on invasion of breast cancer cells in vitro treated with inhibitor. A: SL0101 inhibited the invasion of MDA-231 but not MCF-7 (B) C: BRD 7389 decreased the invasion of both MDA-231 (C) and MCF-7(D) (*p<0.05, **p<0.01 vs. control without inhibitor).